TerminatedEUCTR 2016-004710-95
Extended-release injectable suspension naltrexone (XR-NTX) as an adjunt pharmacotherapy for prevention of substance use in patients with SUD who are currently in treatment for ADHD: A multicenter r...
This historical record does not confirm current site availability.
Historical research recordSweden
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Sweden
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Terminated
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Beroendecentrum Stockholm
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Sweden
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2016-004710-95
- Official title
Show the full official title
Extended-release injectable suspension naltrexone (XR-NTX) as an adjunt pharmacotherapy for prevention of substance use in patients with SUD who are currently in treatment for ADHD: A multicenter r...
Recruitment & locations
TerminatedSweden
Registry details
Historical country statuses
- Sweden — Prematurely Ended
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Beroendecentrum Stockholm.
Is this study still recruiting?
The historical registry lists this study as terminated.
